NCT05360160View on ClinicalTrials.gov

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

SNDX-5613

Given by PO

DRUG

Venetoclax

Given by PO

DRUG

ASTX727

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Syndax Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER